{
    "clinical_study": {
        "@rank": "30319", 
        "brief_summary": {
            "textblock": "To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients.\n      To determine the antiretroviral activity of CI-1012 when added to combination therapy.  To\n      assess the multiple-dose pharmacokinetic characteristics of CT-1012 when added to\n      combination therapy.  To assess the effect of CI-1012 on the pharmacokinetics of other\n      antiretroviral agents."
        }, 
        "brief_title": "A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Doses are escalated based on safety assessments:  As soon as a dose meets the criteria for\n      \"tolerated\" or \"not tolerated\", doses are escalated or terminated, respectively.  All\n      patients are treated for 2 weeks, with follow-up visits scheduled 1 week and 1 month\n      post-treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Serological evidence of late-stage HIV-1 infection (ELISA and Western Blot).\n\n          -  CD4 T cell count less than or equal to 200 mm3.\n\n          -  HIV-1 RNA greater than or equal to 5,000 copies/mL.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Anti-HIV treatment within 8 weeks prior to entry.\n\n          -  Systemic steroids within 4 weeks prior to entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Treatment with anticancer agents within 4 weeks prior to study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002218", 
            "org_study_id": "278B"
        }, 
        "intervention": {
            "intervention_name": "CI-1012", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "HIV-1", 
            "Dose-Response Relationship, Drug", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palm Springs", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92262"
                    }, 
                    "name": "ViRx Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "ViRx Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Central Florida Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "Natl Institutes of Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Univ of Michigan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84108"
                    }, 
                    "name": "Univ of Utah Med School / Clinical Trials Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002218"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Parke-Davis", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1998"
    }, 
    "geocoordinates": {
        "Central Florida Research Initiative": "28.628 -81.363", 
        "Natl Institutes of Health": "38.985 -77.095", 
        "Univ of Michigan": "42.281 -83.743", 
        "Univ of Utah Med School / Clinical Trials Ctr": "40.761 -111.891", 
        "ViRx Inc": "37.775 -122.419"
    }
}